FCF Fox Corporate Finance | FCF Life Sciences Biotech Venture Capital Monitor - USA - May 2021 - FCF Fox ...
←
→
Page content transcription
If your browser does not render page correctly, please read the page content below
FCF Fox Corporate Finance | FCF Life Sciences Biotech Venture Capital Monitor – USA May 2021 Antibody
Agenda FCF LIFE SCIENCES O V E RV I E W
FCF Life Sciences Overview
Overview Services Facts and Figures
Focus on Biotech, MedTech and HealthTech Collaboration Over Over
Life Sciences
Management Team of
with 100 years EUR 2bn
We advise innovative companies on arranging, structuring and placing equity BioScience in aggregated Life Sciences
Presentation 10
and debt transactions in a holistic financing approach. Valuation and Life Sciences transaction
Integrated based in Munich
YAFO Capital experience volume1
Financial
Modeling
Focus Areas Post- Over 7
Access to
Transaction 80 Leading regularly
FCF advises with its dedicated Life Sciences team on the following Support > 1500
completed Life EIB advisor published Life
international
transaction types: Investor Sciences in Europe Sciences
investors
Screening transactions1 reports
1 including Professionals and Life Sciences Advisors
Investor / IB
Venture China Roadshow Life Sciences Research Series
Equity
Debt Licensing
Due
Diligence
Support Life Sciences Venture Biotech Venture Capital
Capital Monitor – Europe Monitor – US
Equity & Debt
Life Sciences Team Fundraising
Financing
Strategy
Advisory Life Sciences Venture Biotech Licensing
Capital Report Monitor – China
Closing
Assistance
Prof. Dr. Arno Fuchs Dr. Alexandra Dr. Joachim Alexander Kuhn
Horst Domdey CEO Goll M. Greuel Analyst
Life Sciences Life Sciences Life Sciences Term Sheet
Advisor Advisor Advisor Negotiation Biotech Public Equity MedTech Public Equity
IPO Monitor Monitor
Execution
Support
Life
Science
Advisory Life Sciences IPO Life Sciences SPAC
Dr. Axel Polack Claus Schalper Dr. Mathias Enno Spillner Sebastian Board (extract from service
Life Sciences Life Sciences Life Sciences Report Monitor
Schott Sommer portfolio)
Advisor Advisor Director Advisor Associate
3Executive Summary
The Biotech Venture
The Biotech Venture Capital Monitor – USA Recipients
Capital Monitor –
USA is a monthly is a monthly published overview of Biotech companies, displaying The Biotech Venture Capital Monitor – USA targets the following
published overview venture capital financing trends in the US-Biotech industry recipients:
focusing on the ▪ Corporates / Executives ▪ Venture capital investors
venture capital ▪ Institutional investors ▪ Family Offices / High-net-
financing ▪ Private equity investors worth individuals
environment in the ▪ Advisors
US-Biotech Scope
segment, and can be
used as a quick The selection of companies is based on the following criteria: Availability
reference for
investors, corporates ▪ Focus on transactions with US-based Biotech companies and The Biotech Venture Capital Monitor – USA is available on FCF’s
and professionals available deal volume website at “https://www.fcf.de/life-sciences/”
▪ Companies operating in the Biotech sector
Data
▪ The Biotech sector is further divided into the following indications:
More advanced, Cardiovascular, Central Nervous System, Dermatology, Ear All input data is provided by Pitchbook or GlobalData and is not
detailed and / or Nose Throat Disorders, Gastrointestinal, Genetic Disorders, independently verified by FCF. Ratio and multiple calculations are
customized reports Genito Urinary System And Sex Hormones, Hematological driven based on the input data available. For additional information
are available upon Disorders, Hormonal Disorders, Immunology, Infectious Disease, and disclaimer, please refer to the last page
request Male Health, Metabolic Disorders, Mouth and Dental Disorders,
Musculoskeletal, Non Malignant Disorders, Nutritional Disorders,
Oncology, Ophthalmology, Respiratory, Toxicology, Women's
Health
To recommend colleagues or fellow investors to be added to the If you have questions, comments or ideas, please do not hesitate to
mailing list, kindly send an email with the respective contact contact us
information
4Agenda B I O T E C H V E N T U R E C AP I TAL T R AN S AC T I O N S - U S A M AY 2 0 2 1
Biotech Venture Capital Transactions - USA
May 2021
Deal Total
Vertical - Indication / Volume Raised
Overview (YTD) # Date Company Stage Company Description Series (USDm) (USDm) Deal Synopsis
Cumulative Financing Volume (USDm)
Oncology / Developer of a biotech company intended
1 31-05-21 Peptinovo Biopharma -Biotech Venture Capital Transactions - USA
May 2021
Deal Total
Vertical - Indication / Volume Raised
Overview (YTD) # Date Company Stage Company Description Series (USDm) (USDm) Deal Synopsis
Cumulative Financing Volume (USDm) Developer of a transdermal patch
Toxicology /
9 26-05-21 Starton Therapeutics technology designed to help people with -Biotech Venture Capital Transactions - USA
May 2021
Deal Total
Vertical - Indication / Volume Raised
Overview (YTD) # Date Company Stage Company Description Series (USDm) (USDm) Deal Synopsis
Cumulative Financing Volume (USDm) Developer of antibody delivery system The company raised $24 million of Series A venture funding on May 20, 2021, putting the
Other /
17 20-05-21 RenBio intended to change the antibody treatment A 24 28 company's pre-money valuation at $18 million. The funds will be used to complete IND-
25,000 On market
landscape. enabling preclinical studies and initiate a Phase 1/2 clinical trial of RB-100 in 2021.
20,000
14,538
15,000
Provider of bio-pharmaceutical services
10,000 Central Nervous intended to offer a novel approach to The company raised $956,905 of venture funding on May 20, 2021. As a part of the transaction,
18 20-05-21 Cytogel Pharma System / deliver pain relief while avoiding several of -Biotech Venture Capital Transactions - USA
May 2021
Deal Total
Vertical - Indication / Volume Raised
Overview (YTD) # Date Company Stage Company Description Series (USDm) (USDm) Deal Synopsis
Cumulative Financing Volume (USDm) Genito Urinary
Developer of novel drugs designed to
System And Sex
25 17-05-21 Lipella Pharmaceuticals facilitate treatment for the hemorrhagic - 3 4 The company raised $3.12 million of venture funding on May 17, 2021.
25,000 Hormones /
cystitis.
Phase II
20,000
14,538
15,000
10,000 Developer of silver chitosan active
Infectious Disease / The company raised $252,000 of angel funding on May 17, 2021, putting the company's pre-
26 17-05-21 Chitozan Health ingredient designed for protection against -Biotech Venture Capital Transactions - USA
May 2021
Deal Total
Vertical - Indication / Volume Raised
Overview (YTD) # Date Company Stage Company Description Series (USDm) (USDm) Deal Synopsis
Cumulative Financing Volume (USDm) Developer of innovative gene therapy
Genetic Disorders / designed to treat rare diseases
33 12-05-21 Apic Bio - 5 47 The company raised $4.74 million of convertible debt financing on May 12, 2021.
25,000 Pre-clinic includingAlpha1 antitrypsin deficiency and
SOD1.
20,000
14,538
15,000
10,000 The company raised $135 million of Series B venture funding on May 11, 2021, putting the
Oncology / Developer of therapies designed to target
34 11-05-21 Nuvalent B 135 185 company's pre-money valuation at $335 million. The funds will be used to advance clinical trials
5,000 Pre-clinic treatment-resistant cancers.
2021 and expand the discovery research pipeline.
2020
0
Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
Financing Volume (May 2021): USD 1,536m
The company raised $52 million of Series A venture funding on May 11, 2021, putting the
Developer of a stem cell therapy
Oncology / company's pre-money valuation at $75 million. The funds will be used to support the
35 11-05-21 Appia Bio technology built to discover safe and A 52 52
Discovery advancement of Appia Bio's pipeline of allogeneic CAR-iNKT cell therapy candidates into the
targeted cancer treatments.
clinic.
Indications Top Investor Origins
Genito Urinary
Others Provider of therapeutic services intended The company raised $40.75 million of Series B venture funding on May 11, 2021. The funding
Adaptive Phage System And Sex
Others 36 11-05-21 to treat multi-drug resistant pathogenic B 41 64 will be used to accelerate the clinical development of phage therapies, as well as for general
16% Therapeutics Hormones /
28%
bacteria. corporate purposes.
Phase II
3%
Oncology
USD 5% USD
46%
14,538m 14,538m
3%
Immunology 3%
9% 76%
Metabolic Developer of eRNA-based therapeutics The company raised $50 million of venture funding on May 10, 2021. The funds will be used to
Disorders
11% Other /
37 10-05-21 Laronde intended to make more predictable and - 50 50 scale its workforce and manufacturing capabilities to enable its bold vision of 100 new eRNA
Infectious On market
impactful medicines for the world. medicines and drug programs within the next decade.
Diseases Central
Nervous
System
The company raised $40 million of Series A venture funding on May 10, 2021, putting the
Top 5 Deals Top 5 Investors Oncology /
Developer of targeted nucleic acid company's pre-money valuation at $45 million. The funds will be used to support the
38 10-05-21 Gennao Bio therapeutics intended to cure muscle A 40 40 advancement of its proprietary, first-in-class gene monoclonal antibody platform (GMAB) and
Pre-clinic
Deal Deal # of
diseases. the development of targeted nucleic acid therapeutic product candidates for the treatment of
# Company HQ Volume Series # Investor HQ Volume1 Deals oncology and rare monogenic skeletal muscle diseases.
Treeline
1 735 A 1 Logos Capital 405 23
Biosciences
Operator of a clinical-stage
ARCH
Oncology / immunotherapy company intended to
2 ElevateBio 525 C 2 Venture 397 11 39 10-05-21 Triumvira Immunologics - 16 84 The company raised $16.21 million of venture funding on May 10, 2021.
Phase II develop novel T-cell therapies for cancer
Partners
treatment.
Casdin
3 EQRx 525 B 3 285 15
Capital
RA Capital Developer of a RUC-4 novel small
4 Instil Bio 356 B 4 257 26
Management Cardiovascular / molecule inhibitor designed to be the first
40 10-05-21 CeleCor Therapeutics - 1 1 The company raised $1 million of angel funding on May 10, 2021.
Phase II point of contact treatment for segment
Adagio elevated myocardial infarction (STEMI).
5 336 C 5 GV 246 11
Therapeutics
Source: PitchBook as of 21-06-2021; FCF Equity Research; GlobalData
Note: All volumes in USDm; financing rounds without deal values are excluded 10
1 Proportional attribution of deal values to investors participating in a transaction (transaction volume / # investors by financing round)Biotech Venture Capital Transactions - USA
May 2021
Deal Total
Vertical - Indication / Volume Raised
Overview (YTD) # Date Company Stage Company Description Series (USDm) (USDm) Deal Synopsis
Cumulative Financing Volume (USDm) Developer of a porous microneedle
Other /
41 06-05-21 Anodyne Nanotech technology designed to redefine drug - 2 6 The company raised $1.96 million of convertible debt financing on May 6, 2021.
25,000 Pre-clinic
delivery.
20,000
14,538
15,000
10,000 The company raised $40 million of Series B venture on May 6, 2021. This round of financing
Oncology / Developer of biopharmaceuticals intended
42 06-05-21 Phanes Therapeutics B 40 55 will be used to accelerate the clinical transformation of multiple anti-tumor products in the R&D
5,000 Pre-clinic to treat oncology and eye diseases.
2021 pipeline.
2020
0
Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
Financing Volume (May 2021): USD 1,536m
Central Nervous Developer of central nervous system The company raised $34.70 million of Series A venture funding on May 6, 2021. The funds will
43 06-05-21 Gilgamesh System / drugs intended to treat neurological A 35 35 be used to add more members to the team and for advancing programs toward clinical
Discovery disorders. candidate selection and broadcasting its IP portfolio.
Indications Top Investor Origins
Developer of tissue factor (TF)
Others
Eikonoklastes Oncology / immunotherapies designed to assist in the The company raised $6 million of Series A venture funding on May 6, 2021, putting the
Others 44 06-05-21 A 6 9
16% Therapeutics Discovery treatment of solid tumors and other company's pre-money valuation at $20 million.
28% pathologic conditions.
3%
Oncology
USD 5% USD
46%
14,538m 14,538m
3%
Immunology 3%
9% 76%
Metabolic Developer of regulatory therapeutics
Disorders
11% Oncology / The company raised $352,181 of venture funding in the form of convertible debt on May 6,
45 06-05-21 Acworth Pharmaceuticals created to kill cancer by restoring normal -Biotech Venture Capital Transactions - USA
May 2021
Deal Total
Vertical - Indication / Volume Raised
Overview (YTD) # Date Company Stage Company Description Series (USDm) (USDm) Deal Synopsis
Operator of a specialty pharmaceutical
Cumulative Financing Volume (USDm) Central Nervous company intended to develop novel
MAXONA
49 05-05-2021 System / therapeutics for the treatment of moderate - 6 6 The company raised $5.56 million of angel funding on May 5, 2021.
25,000 Pharmaceuticals
Phase I to severe pain without opioid and NSAID-
associated side effects.
20,000
14,538
15,000
10,000
Infectious Disease / Developer of peptide vaccine intended to
50 05-05-2021 Kermode Biotechnologies - 1 1 The company raised $1.2 million of angel funding on May 5, 2021.
5,000 2021 Undisclosed solve the challenges of animal health.
2020
0
Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
Financing Volume (May 2021): USD 1,536m
Producer of medical cannabis products
Silverleaf Health Other / intended to provide diverse therapeutic The company raised $3.92 million of Series A Angel funding on May 4, 2021, putting the
51 04-05-2021 A 4 4
Alternatives Discovery technologies for patients suffering from company's pre-money valuation at $9 million.
epilepsy and chronic pain.
Indications Top Investor Origins
Others Provider of diagnostic and pharmaceutical
Others Oncology / products intended to use for the treatment
16% 52 04-05-2021 Imcare biotech - 2 2 The company raised $1.78 million of angel funding on May 4, 2021.
28%
Discovery of cancers, viral infections and other long-
Oncology
3% term illnesses.
USD 5% USD
46%
14,538m 14,538m
3%
Immunology 3%
9% 76%
Metabolic
11% Operator of a drug development company The company raised $6 million of Series A venture funding on May 3, 2021, putting the
Disorders Astrocyte Oncology /
Infectious 53 03-05-2021 dedicated to clinically proving the A 6 8 company's pre-money valuation at $10 million. The funding enables the company to advance
Pharmaceuticals Pre-clinic
Diseases Central neuroprotective benefits. AST-004 into human Phase I clinical studies.
Nervous
System
Top 5 Deals Top 5 Investors
Developer of novel anti-cancer and anti-
Oncology /
54 03-05-2021 Decoy Biosystems viral immunotherapy designed to eliminate - 6 14 The company raised $6.42 million of venture funding on May 3, 2021.
Deal Deal # of Pre-clinic
viral and bacterial infections.
# Company HQ Volume Series # Investor HQ Volume1 Deals
Treeline
1 735 A 1 Logos Capital 405 23
Biosciences
ARCH
Operator of a biotechnology company
2 ElevateBio 525 C 2 Venture 397 11 Other /
55 03-05-2021 Seranova Bio intended to offer therapeutic target drug - 5 5 The company raised $5.05 million of angel funding on May 3, 2021.
Partners On market
discovery.
Casdin
3 EQRx 525 B 3 285 15
Capital
Developer of immunotherapies designed
RA Capital to fight cancer, infectious disease, and
4 Instil Bio 356 B 4 257 26 autoimmune disorders. The company
Management Oncology /
56 03-05-2021 AVM Biotechnology develops a proprietary and innovative - 4 15 The company raised $4.43 million of venture funding on May 3, 2021.
Phase II
form of dexamethasone that mobilizes
Adagio very active natural killer T-cells and
5 336 C 5 GV 246 11
Therapeutics cytotoxic T-cells.
Source: PitchBook as of 21-06-2021; FCF Equity Research; GlobalData
Note: All volumes in USDm; financing rounds without deal values are excluded 12
1 Proportional attribution of deal values to investors participating in a transaction (transaction volume / # investors by financing round)Biotech Venture Capital Transactions - USA
May 2021
Deal Total
Vertical - Indication / Volume Raised
Overview (YTD) # Date Company Stage Company Description Series (USDm) (USDm) Deal Synopsis
Cumulative Financing Volume (USDm) Producer of cannabidiol (CBD) consumer
Other / products intended to shape the CBD
57 03-05-2021 Kadenwood -Contact Details & Disclaimer
DISCLAIMER
This document does not constitute an offer or invitation to purchase or
subscribe for any securities, and neither this document nor anything contained
herein shall form the basis of or may be relied upon in connection with any
contract or commitment whatsoever. No representation or warranty (express or
FCF Fox Corporate Finance GmbH implied) is made as to, and no reliance should be placed on, any information,
including projections, estimates, targets and opinions, contained herein, and no
Maximilianstrasse 12-14 ▪ 80539 Munich ▪ Germany liability whatsoever is accepted as to any errors, omissions or misstatements
Telephone +49 (89) 206 0409-0 ▪ Facsimile +49 (89) 206 0409-299 contained herein, and, accordingly, neither FCF nor any of its officers, directors
info@fcf.de ▪ www.fcf.de or employees accepts any liability whatsoever arising directly or indirectly from
the use of this document. By accepting this document you acknowledge that
you will be solely responsible for your own assessment of the market and the
market position of the Company and that you will conduct your own analysis
and be solely responsible for forming your own view of the potential future
Arno Fuchs Dr. Mathias Schott performance of the Company's business. This document contains certain
Chief Executive Officer Director
forward-looking statements, including assumptions, opinions and views cited
P: +49 (89) 206 0409-100 P: +49 (89) 206 0409-123 from third party sources. Various known and unknown risks, uncertainties and
M: +49 (172) 863 6777 M: +49 (174) 301 1846
other factors could cause the actual results, financial position, development or
arno.fuchs@fcf.de mathias.schott@fcf.de
performance of the Company to differ materially from the estimations
expressed or implied herein. FCF does not guarantee that the figures,
assumptions and calculations underlying such historical and forward looking
Sebastian Sommer Alexander Kuhn statements are free from errors nor does FCF accept any responsibility for the
Associate Analyst
future accuracy of the opinions expressed in this document or the actual
P: +49 (89) 206 0409-130 P: +49 (89) 206 0409-120 occurrence of the forecasted developments.
M: +49 (172) 839 5738 M: +49 (173) 590 6671
sebastian.sommer@fcf.de alexander.kuhn@fcf.de © FCF Fox Corporate Finance GmbH 2021You can also read
